Daiichi Sankyo announced that Hiroyuki Okuzawa will serve as its new CEO starting on April 1, 2025. 1 The previous CEO, Sumao ...

IHH’s subsidiary Northern TK Venture (NTK) had filed a claim against Daiichi Sankyo saying the latter prevented NTK from ...

Japanese drugmaker Daiichi Sankyo has appointed Hiroyuki Okuzawa to succeed Sunao Manabe, as chief executive (CEO), effective ...

Delhi: IHH Healthcare, a prominent global healthcare provider, has escalated its legal battle with Japan's Daiichi Sankyo, ...

Big Pharma often turns to NFL games to hawk their blockbuster treatments, but drug makers have typically been hesitant to ...

PETALING JAYA: The tussle between IHH Healthcare Bhd, Asia’s biggest private healthcare provider, and Daiichi Sankyo Co Ltd, a pharmaceutical firm, over IHH’s open offer for the 26% of shares ...

Under Dr Manabe’s leadership, Daiichi Sankyo’s pioneering science and technology led to the resurgence of antibody drug conjugate (ADC) development within the pharmaceutical industry, leading to three ...

AN INDIRECT, wholly owned subsidiary of integrated healthcare player IHH Healthcare, Northern TK Venture (NTK), on Thursday ...

The company had initially claimed 20 billion yen ($130.99 million) that Daiichi was ordered to pay as damages to NTK in ...

IHH Healthcare seeks ₹10,930 crore compensation from Daiichi Sankyo for Fortis Healthcare stake buy legal dispute.

Tokyo: Daiichi Sankyo Company, Ltd has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive ...